10.21.13
The world has changed quite drastically since Moximed Inc. debuted its knee osteoarthritis treatment in 2008.
The most devastating global economic crisis since the Great Depression doubled the U.S. unemployment rate and annihilated more than 7.5 million jobs; America's housing market collapsed and equity market fluctuations destroyed trillions of dollars in personal wealth; voters elected the nation's first African-American president; Facebook grew 10-fold (in users); consolidation in the medtech industry has shrunk the supply chain; 3-D printing has created endless possibilities in regenerative medicine; and venture capital funding for medical device companies has become nearly as scarce as a clearly-defined regulation from the U.S. Food and Drug Administration (FDA).
The first KineSpring device was implanted by David Hayes, M.D., of the Brisbane Orthopaedic and Sports Medicine Centre in Australia. Over the last five years, surgeons have implanted Moximed's product in hundreds of patients with knee osteoarthritis (OA), a disease that affects more than 15 million U.S. residents and costs the country's bloated healthcare system nearly $300 billion annually, according to industry estimates.
Earlier this fall, Jack Farr, M.D., director of the OrthoIndy Cartilage RestorationCenter of Indiana and the OrthoIndy Sports Medicine Fellowship Program, implated the 500th KineSpring device. "I continue to be impressed by the potential of the unloading concept as a treatment option for patients with knee OA," said Farr, who also is lead principal investigator of the U.S.-based SOAR clinical study of the KineSpring System. "My experience has validated significant patient interest in the KineSpring System, and I am encouraged by the positive outcomes that have been generated by surgeons in Australia and Europe."
Moximed's KineSpring System is a partial load absorber that reduces knee joint load by up to 13 kg. The absorber is implanted in the extra-capsular space along the medial side of the joint, and it actively unloads the knee during the stance phase of gait. Moximed claims the KineSpring is joint sparing: Since the device is extra-capsular and extra-articular, no bone, ligament or cartilage is removed. Thus, the procedure is reversible.
"The KineSpring System offers a joint-preserving surgical alternative for my younger, more active patients with medial knee OA," Hayes noted. "Five years after implanting the first ever KineSpring System, I remain enthusiastic about the potential of the KineSpring System as an effective treatment option for this difficult patient group."
The KineSpring System is CEmarked in Europe but only is used investigationally in the United States as part of the FDA-approved SOAR clinical study.
"The growing acceptance of the KineSpring System, as evidenced by the achievement of this milestone, is very encouraging. We are most proud to have played a part in the return of a significant number of patients to an active, high-quality lifestyle,"Moximed President/CEOKevin Sidow said.
Based in Hayward, Calif., Moximed develops minimally invasive, joint-preserving solutions for knee OA patients. The company is supported by various venture investors, including New Enterprise Associates, Morgenthaler Ventures, Frazier Healthcare Ventures, Glide Healthcare Partners, and GBSVenture Partners.
The first KineSpring device was implanted by David Hayes, M.D., of the Brisbane Orthopaedic and Sports Medicine Centre in Australia. Over the last five years, surgeons have implanted Moximed's product in hundreds of patients with knee osteoarthritis (OA), a disease that affects more than 15 million U.S. residents and costs the country's bloated healthcare system nearly $300 billion annually, according to industry estimates.
Earlier this fall, Jack Farr, M.D., director of the OrthoIndy Cartilage RestorationCenter of Indiana and the OrthoIndy Sports Medicine Fellowship Program, implated the 500th KineSpring device. "I continue to be impressed by the potential of the unloading concept as a treatment option for patients with knee OA," said Farr, who also is lead principal investigator of the U.S.-based SOAR clinical study of the KineSpring System. "My experience has validated significant patient interest in the KineSpring System, and I am encouraged by the positive outcomes that have been generated by surgeons in Australia and Europe."
Moximed's KineSpring System is a partial load absorber that reduces knee joint load by up to 13 kg. The absorber is implanted in the extra-capsular space along the medial side of the joint, and it actively unloads the knee during the stance phase of gait. Moximed claims the KineSpring is joint sparing: Since the device is extra-capsular and extra-articular, no bone, ligament or cartilage is removed. Thus, the procedure is reversible.
"The KineSpring System offers a joint-preserving surgical alternative for my younger, more active patients with medial knee OA," Hayes noted. "Five years after implanting the first ever KineSpring System, I remain enthusiastic about the potential of the KineSpring System as an effective treatment option for this difficult patient group."
The KineSpring System is CEmarked in Europe but only is used investigationally in the United States as part of the FDA-approved SOAR clinical study.
"The growing acceptance of the KineSpring System, as evidenced by the achievement of this milestone, is very encouraging. We are most proud to have played a part in the return of a significant number of patients to an active, high-quality lifestyle,"Moximed President/CEOKevin Sidow said.
Based in Hayward, Calif., Moximed develops minimally invasive, joint-preserving solutions for knee OA patients. The company is supported by various venture investors, including New Enterprise Associates, Morgenthaler Ventures, Frazier Healthcare Ventures, Glide Healthcare Partners, and GBSVenture Partners.